Entering text into the input field will update the search result below

Catalyst Pharma rises on positive outcome in Firdapse cardiac safety trial

Jan. 08, 2014 8:34 AM ETCatalyst Pharmaceuticals, Inc. (CPRX) StockBy: Colin Lokey, SA News Editor1 Comment
  • Catalyst Pharmaceutical (NASDAQ:CPRX) rallies 15% premarket.
  • The company says a jointly funded study with BioMarin (BMRN) to examine the cardiac safety of Firdapse hit its primary endpoint.
  • "At and above therapeutic levels, there was no effect of Firdapse on heart rate or cardiac depolarization," CPRX says.
  • The company hopes the results "will continue to work toward making Firdapse available to patients in the U.S." (PR)

Recommended For You

About CPRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CPRX--
Catalyst Pharmaceuticals, Inc.